In a significant step toward taming one of the most lethal forms of prostate cancer, a team led by Umeå University has developed a fully human antibody that, in preclinical models, simultaneously shuts down tumor growth and blocks the metastatic spread that makes the disease so deadly. The findings, published in Signal Transduction and Targeted Therapy, detail a novel strategy that disrupts a specific molecular engine driving androgen-independent prostate cancer, a notoriously aggressive subtype for which few effective treatments exist once hormone therapies fail.
Prostate cancer remains the second most common cancer in men worldwide, and while many cases are slow-growing, a fraction evolve into castration-resistant tumors that invade lymph nodes and bone. This metastatic cascade is orchestrated by reprogrammed signaling networks, among them the transforming growth factor-beta (TGF-β) pathway. In advanced disease, TGF-β switches from a tumor-suppressive brake to an oncogenic accelerator, promoting epithelial-to-mesenchymal transition, immune evasion, and tissue invasion. The new antibody zeroes in on a key receptor in this pathway: the type I TGF-β receptor, TβRI, whose aberrant activity helps prostate cancer cells flourish without androgens and colonize distant organs.
By locking onto TβRI, the antibody interrupts a phosphorylation cascade that would otherwise feed the tumor’s invasive machinery. In the study, researchers tested the drug candidate across a range of aggressive prostate cancer cell lines and in mouse xenograft models that mimic human metastatic disease. The antibody not only slashed primary tumor growth but also markedly reduced the number and size of metastases in bone and soft tissues. Importantly, the treatment did not broadly suppress all TGF-β signaling, sparing the pathway’s homeostatic roles in normal tissues, which the team attributes to the antibody’s precise epitope recognition. This selectivity is expected to translate into a cleaner safety profile compared to small-molecule kinase inhibitors that often hit multiple targets.
A crucial advantage of the molecule is its fully human amino acid sequence, derived from phage-display libraries rather than from animal immunization. Fully human antibodies carry a lower risk of triggering unwanted immune reactions when administered to patients, thereby streamlining the transition from bench to bedside. Maréne Landström, Professor of Pathology at Umeå University and senior author of the study, notes that this feature, combined with the unique mechanism of action, gives the candidate a realistic shot at becoming a first-in-class therapeutic for men with advanced prostate cancer who have exhausted standard hormonal and chemotherapeutic options.
The development effort spanned several years and relied on a network of collaborators. The antibody was matured and validated with the support of the SciLifeLab Drug Discovery and Development Platform, while the Umeå Biotech Incubator provided translational expertise. Financial backing came from MetaCurUm Biotech AB, the Knut and Alice Wallenberg Foundation, the Swedish Cancer Society, and the Swedish Research Council, among others. “We are very pleased and proud that we have been able to identify the mechanisms that drive cancer cell growth, invasiveness, and metastatic spread,” Landström said, emphasizing that the work represents a true convergence of academic discovery and industrial drug development know-how.
Despite the promising preclinical data, Landström is careful to temper expectations. The antibody must undergo rigorous toxicology studies and satisfy regulatory requirements in Europe or the United States before entering clinical trials. The next phases will involve scaled-up manufacturing under good manufacturing practices, extended safety pharmacology, and dose-optimization studies. “This is a promising step forward, but several important stages remain before the treatment can benefit patients,” she added.
The study also opens a wider therapeutic window. Because oncogenic TβRI signaling fuels tumor progression in a variety of epithelial cancers—including those of the breast, lung, and pancreas—the antibody could be repurposed for other solid tumors that hijack the same pathway. The team is already designing experiments to test the candidate in additional disease models, hoping to establish the generality of the approach.
The paper appears in Signal Transduction and Targeted Therapy, a high-impact journal of the Nature Portfolio, with the full author list comprising researchers from Umeå University, the Institute of Cancer Research in London, and other international centers. The article title, “Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis,” underscores the translational ambition: to turn a fundamental insight about a signaling receptor into a tangible drug that could one day extend lives. As the global burden of metastatic prostate cancer rises, this antibody offers a fresh blueprint for targeting the molecular underpinnings of tumor aggression without the collateral damage that has long plagued conventional treatments.
Subject of Research: Cells
Article Title: Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis
News Publication Date: 17-Jun-2026
Web References: http://dx.doi.org/10.1038/s41392-026-02737-x
References: Flodbring Larsson P, Schmidt A, Mu Y, Zang G, Song J, Gajavilli V, Tao J, Rakhimova O, Ericsson M, Aripaka K, Halin Bergström S, Yuan W, Bogdan D, Zhang AH, Welti J, Bergh A, de Bono J, Heldin CH, Landström M. Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis. Signal Transduction and Targeted Therapy. 2026 Jun 17;11(1):238. DOI: 10.1038/s41392-026-02737-x. PMID: 42303991. PMCID: PMC13272619.
Image Credits: Umeå University
Keywords: prostate cancer, metastasis, antibody therapy, TβRI, TGF-beta signaling, targeted therapy, fully human antibody, preclinical study
